CA125 phosphorylation is associated with its secretion from the wish human amnion cell line

Tumor Biology

Volumn 18, Issue 5, 1997, Pages 278-289

  Fendrick, James L ^a   Konishi, Ikuo ^a,b   Dudich, Sínead M ^a   Parmley, Timothy H ^a   Quirk, Gerald ^a   O’brien, Timothy J ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

CA125; Ovarian cancer; Phosphoproteins; Secretion; Vanadate; WISH cells

Indexed keywords

CA 125 ANTIGEN; EPIDERMAL GROWTH FACTOR; HYDROGEN PEROXIDE; MONOCLONAL ANTIBODY; PHOSPHATE; PHOSPHOPROTEIN; PHOSPHORUS 32; TYROSINE; VANADIC ACID;

AMNION CELL; ARTICLE; CELL LINE; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION;

EID: 0030744583     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1159/000218041     Document Type: Article

References (44)

1. Kabawat SE, Bast RC Jr, Welch WR, Knapp RC, Colvin RB: Immu-nopathologic characterization of a monoclonal antibody that recognizes common surface antigens on human ovarian tumors of serous, endometrioid, and clear cell types, Am J Clin Pathol 1983;79:98-104.
2. Bast RC Jr, Klug TL, St John E, et al: A radioimmunoassay using monoclonal antibody to monitor the course of epithelial ovarian cancer, N Engl J Med 1983;309:883-887.
3. Klug TL, Bast RC Jr, Nilofif JM, Knapp RC, Zurawski VR Jr: Monoclonal antibody immunoradiomet-ric assay for an antigenic determinant (CA125) associated with human epithelial ovarian carcinomas, Cancer Res 1984;44:1048-1053.
4. Canney PA, Moore M, Wilkinson PM, James RD: Ovarian cancer antigen CA125: A prospective clinical assessment of its role as a tumor marker, Br J Cancer 1984:50:765-769.
5. Bast RC Jr, Feeny M, Lazarus H, Nadler LM, Colvin RB, Knapp RC: Reactivity of a monoclonal antibody with human ovarian carcinoma, J Clin Invest 1981;68:1331-1337.
6. Hanisch FG, Uhlenbruck G, Dienst C, Stottrop M, Hippaunf E: CA125 and CA19-9: 2 cancer-associated sialysaccharidc antigens on a mucus glycoprotein from human milk, Eur J Biochem 1985:149:323-330.
7. de Bruijn HW, van Beeck Calkoen-Carpay T, Jagcr S, Duk JM, Aalders JG, Fleuren GJ: The tumor marker CA125 is a common constituent of normal cervical mucus, Am J Obstct Gynecol 1986;154:1088-1091.
8. Jacobs I, Bast RC Jr: The CA125 tumor-associated antigen: A review of the literature, Hum Rcprod 1989; 4:1-12.
9. Jacobs IJ, Fay TN, Yovich J, et al: Serum levels of CA125 during the first trimester of normal outcome, ectopic and abcmbryonic pregnancies, Hum Rcprod 1990:5:116-122.
10. O'Brien TJ, Hardin JW, Bannon GA, Norris JS, Quirk JG Jr: CA125 antigen in human amniotic fluid and fetal membranes, Am J Obstet Gynecol 1986:155:50-55.
11. Patton PE, Field CS, Harms RW, Coulam CB: CA-125 levels in endometriosis, Fertil Steril 1986;45: 770-773.
12. Kabawat SE, Bast RC Jr, Bhan AK, Welch WR, Knapp RC, Colvin RB: Tissue distribution of a coelomic-epithclium-related antigen recognized by the monoclonal antibody OC125, Ir.t J Gynecol Pathol 1983: 2:275-285.
13. Hardardottir H, Parmley TH, Quirk JG Jr, Sanders MM, Miller FC, O’Brien TJ: Distribution of CA125 in embryonic tissues and adult derivatives of the fetal periderm, Am J Obstet Gynecol 1990:163:1925- 1931.
14. O’Brien TJ, Raymond LM, Bannon GA, et al: New monoclonal antibodies identify the glycoprotein earning the CAI25 epitope, Am J Obstet Gynecol 1991; 165:1857- 1864.
15. Niloff JM, Knapp RC, Schactzl EM, Reynolds C, Bast RC Jr: CA125 antigen levels in obstetrics and gynecologic patients, Obstet Gynecol 1984: 64:703-707.
16. Quirk JG Jr, Brunson GL, Long CA, Bannon GA, Sanders MM, O'Brien TJ: CA125 in tissues and amniotic fluid during pregnancy, Am J Obstct Gynecol 1988:159:644-649.
17. Hosono MN, Endo K, Sakahara H, et al: Different antigenic nature in apparently healthy women with high scrum CA125 levels compared with typical patients with ovarian cancer, Cancer 1992:70:2851-2856.
18. Kacinski BM, Chambers SK: Molecular biology of ovarian cancer, Curr Opin Oncol 1991;3:889-900.
19. Konishi I, Fendrick JL, Parmlcy TH, Quirk JG Jr, O'Brien TJ: Epidermal growth factor enhances secretion of the ovarian tumor-associated antigen CA125 from the human amnion WISH cell line, J Soc Gynecol Invest 1994:1:89-96.
20. Volbcrg T, Zick Y, Dror R, et al: The effect of tyrosine-specific protein phosphorylation on the assembly of adherens-type junctions, EMBOJ 1992;11:1733-1742.
21. Fendrick JL, Staley KA, Gee MK, McDougald SR, Quirk JG Jr, O’Brien TJ: Characterization of CAI25 synthesized by the human epithelial amnion WISH cell line, Tumor Biol 1993;14:310-318.
22. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4, Nature 1970:227:680-685.
23. Towbin H, Stachelin T, Gordon J: Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedures and some applications, Proc Natl Acad Sci USA 1979:76:4350-4354.
24. Kamps MP: Determination of phos-phoamino acid composition by acid hydrolysis of protein blotted to im-mobilon, Methods Enzymol 1991; 201:21-27.
25. Gordon JA: Use of vanadate as a protcin-phosphotyrosine phosphatase inhibitor, Methods Enzymol 1991;202:477-482.
26. Ullrich A, Schlessinger J: Signal transduction by receptors with tyrosine kinase activity, Cell 1990:61: 203-212.
27. Klarlund JK: Transformation of cells by an inhibitor of phosphatases acting on phosphotyrosine in proteins, Cell 1985:41:707-717.
28. LaPolt PS, Tsafriri A, Bicsak TA, Ny T, Hsuch AJW: Changes in tissue-type plasminogen activator levels during ovulation, oocyte maturation and early embryonic development; in Tsafrir A, Dekcl N (eds): Follicular Development and Ovulatory Response, Ares-Serono Symp, Rome, Italy, pp 159-168.
29. George F, Pourrcau-Schneider N, Arnoux D, et al: Concomitant secretion by A431 cells of tissue plasminogen activator and a specific inhibitor masks EGF modulation of tPA activity, Thromb Haemost 1990:64: 407-411.
30. Stopelli MP, Verde P, Grimaldi G, Locatelli E, Blasi F: Increase in urokinase plasminogen activator mRNA synthesis in human carcinoma cells is a primary effect of the potent tumor promoter, phorbol myristatc acetate, J Cell Biol 1986; 102:1235-1241.
31. Busso N, Nasur SK, Lazega D, Wax-man S, Ossowski L: Induction of cell migration by prourokinasc binding to its receptor: Possible mechanism for signal transduction in human epithelial cells, J Cell Biol 1994:126: 259-270.
32. Takahashi K, Kwaan HC, Koh E, Tanabc M: Enzymatic properties of the phosphorylated urokinase-type plasminogen activator isolated from human carcinomatous cell line, Bio-chem Biophys Res Commun 1992; 182:1473-1481.
33. Schonthal A, Fcramisco JR: Inhibition of histone HI kinase expression, retinoblastoma protein phosphorylation, and cell proliferation by the phosphatase inhibitor, okada-ic acid, Oncogene 1993:8:433-441.
34. Akiyama T, Ogawara H: Use and specificity of genistcin as inhibitor of protcin-tyrosine kinases, Methods Enzymol 1991,201:362-370.
35. Hidaka H, Watanabe M, Kobayashi R: Properties and use of H-scrics compounds as protein kinase inhibitors, Methods Enzymol 1991,201: 328-339.
36. Tamaoki T: Use and specificity of staurosporine, UCN-01, and cal-phostin C as protein kinase inhibitors, Methods Enzymol 1991:201: 340-347.
37. Kniss DA, Mershon J, Su H-C, et al: Evidence of a role for protein kinase C in epidermal growth factor-induced prostaglandin E2 synthesis in amnion cells, Am J Obstct Gynecol 1990:163:1883-1890.
38. Su H-C, Fcrtel RH, Kniss DA: Catecholamines modulate epidermal growth factor-induced prostaglandin E2 production in amnion-like (WISH) cell by means of a cyclic adenosine monophosphate dependent pathway, Am J Obstct Gynecol 1992:166:236-241.
39. Pazin MJ, Williams LT: Triggering signaling cascades by receptor tyrosine kinases, Trends Biochcm Sci 1992;17:374-378.
40. Nagata A, Hitroto N, Sakai T, Fuji-moto M, Komoda T: Molecular nature and possible presence of a membranous glycan-phosphatidyl-inositol anchor of CA125 antigen, Tumor Biol 1991;12:279-286.
41. Korte K, Casey ML: The effects of vanadate and epidermal growth factor on the specific activities of phos-pholipasc A2 and phosphatidylino-sitol-specific phospholipase C in human amnion cells, Clin Exp Obstct Gynecol 1993:20:159-163.
42. Nishibc S, Wahl MI, Wcdegacrtncr PB, Kim JW, Rhee SG, Carpenter G, Kim JW: Selectivity of phospholipase C phosphorylation by the epidermal growth factor receptor, the insulin receptor, and their cytoplasmic domains, Proc Natl Acad Sci USA 1990:87:424-428.
43. Nanbu Y, Fujii S, Konishi I, Nono-gaki H, Mori T: CA125 in the epithelium closely related to the embryonic ectoderm: The periderm and the amnion, Am J Obstct Gynecol 1989:161:462-467.
44. Hardic DG, Haystcad TAJ, Sim ATR: Use of okadaic acid to inhibit protein phosphatases in intact cells, Methods Enzymol 1991:201:469-476.